Tests lowering heart failure medicine doses in patients whose heart failure is in remission
Tests whether reducing heart failure medicines is safe in adults with heart failure in remission.
Plain-language title generated from the registry record
Registry title: A trial investigating partial withdrawal of heart failure therapy in patients with heart failure in remission.
Key facts
- Where
- Genk, Hasselt, and Turnhout, BelgiumSee the 3 sites
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose heart failure is in remission and who take at least 3 heart failure medicines at stable, maximally tolerated doses. It tests lowering some of these medicines against keeping them.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Heart failure in remission: LVEF above 50%, normal heart volumes, NT-proBNP ≤ 250 pg/mL, normal functional capacity and clinical stability.
- Earlier treatment
- Must take at least 3 heart failure therapies (ACEi/ARB/ARNI, BB, and MRA or SGLT2i), each at the maximally tolerated dose and stable for at least 6 months before screening.
- Biomarker or test result
- NT-proBNP ≤ 250 pg/mL
Main reasons for not taking part
- Albuminuric chronic kidney disease
- Major heart or brain event (acute coronary syndrome, CABG, stroke or TIA) in the 90 days before screening
- Uncontrolled hypertension
- Atrial fibrillation or atrial flutter with a resting heart rate >110 beats per minute
- Pregnant or breastfeeding women
Read by machine on 9 November 2026.
Where in Belgium
- Ziekenhuis Oost-LimburgGenk, BelgiumTaking people
- JESSA ZiekenhuisHasselt, BelgiumTaking people
- AZ TurnhoutTurnhout, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorTrial details
- Who runs it
- Ziekenhuis Oost Limburg
- Trial code
- EU 2025-522560-32-01
- Record updated
- 9 October 2026
- Original description
To investigate the safety and feasibility of heart failure therapy down-titration versus therapy continuation in patients with heart failure in remission.Read full original descriptionShow less
A prospective, randomized, controlled clinical pilot trial investigating the partial down-titration of guideline-directed medical therapy in patients with heart failure in remission
To investigate the safety and feasibility of heart failure therapy down-titration versus therapy continuation in patients with heart failure in remission.
Inclusion: Adults aged ≥ 18 years; Heart failure in remission, defined as heart failure with an improved ejection fraction to an LVEF above 50%, with normalized LV volumes, an NT-proBNP ≤ 250 pg/mL, normal functional capacity, and clinical stability; Patients must receive at least 3 HF therapies (ACEi/ARB/ARNI, BB, and MRA or SGLT2i) for HF, consistent with international HF guidelines. Each therapy must have been titrated to the maximally tolerated dose, stable for at least 6 months prior to screening.
Exclusion: Recent major cardiovascular events such as an acute coronary syndrome, CABG, stroke or TIA in the 90 days before screening; Any sustained ventricular arrythmias within 6 months prior to screening; Albuminuric chronic kidney disease; Uncontrolled hypertension; Atrial fibrillation or atrial flutter with a resting heart rate >110 beats per minute; Patients with a cardiac resynchronization therapy device who have < 98% biventricular pacing during screening; Any untreated valvular heart disease of moderate or greater severity during screening; Presence of any other disease with a life expectancy of < 2 years; Pregnant or lactating women.